Monograph Details
|
|
Cardiovascular System
> Hypertension
|
|
TEVETEN |
| Manufacturer |
|
Abbott Laboratories |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Angiotensin II receptor blocker. |
| Generic Name |
|
Eprosartan (as mesylate) 400mg, 600mg; tabs. |
| Indications |
|
Hypertension. |
| Children |
|
Not recommended. |
| Adults |
|
Monotherapy: not volume depleted: initially 600mg once daily. Usual range: 400–800mg/day given as a single dose or in two divided doses. |
| Contraindications |
|
Pregnancy (Cat.D in 2nd and 3rd trimesters). |
| Precautions |
|
Correct salt/volume depletion before beginning therapy or monitor closely. Renal impairment. Renal artery stenosis. Severe CHF. Pregnancy (Cat.C in 1st trimester). Nursing mothers: not recommended. |
| Interactions |
|
Hyperkalemia with K+ supplements, K+ sparing diuretics, K+ containing salt substitutes. |
| Adverse Reactions |
|
Viral infection, injury, fatigue, abdominal pain, hypertriglyceridemia, arthralgia, depression, urinary tract or upper respiratory tract infection, rhabdomyolysis (rare). |
| How Supplied |
|
Tabs—100 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
